Skip to main content

Ciphergen Regains Nasdaq Compliance by Moving to Cap Market

NEW YORK (GenomeWeb News) – Ciphergen Biosystems today said its shares have regained compliance with the Nasdaq exchange after it allowed the company to move its shares to its Capital Market from the National Market.
To remain listed on the Capital Market Ciphergen must, among other things, have a market capitalization greater than $35 million, the company said in a Securities and Exchange Commission filing today. Ciphergen’s market cap is currently around $48 million.
As GenomeWeb News reported in July, the Nasdaq notified Ciphergen that it is subject to delisting from the National Market because its market cap had fallen below $50 million for 10 consecutive business days.
Its stock will trade on the Capital Market on Aug. 28 under the ticker symbol CIPH.
“By transferring from the Nasdaq Global Market to the Nasdaq Capital Market, Ciphergen satisfies the listing requirements” for the exchange, Ciphergen said in statement.
Ciphergen’s “continued listing on the Nasdaq Capital Market is subject to its successful completion of an application and review process,” the company said in the SEC filing.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.